Inicio > Productos > Anticuerpos > Biosimilares

Research Grade Emibetuzumab (HY196016)

Datasheet Compartir producto Copiar información

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Research Grade Emibetuzumab

Precio(USD): $

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet

Vista general

Número de catálogo	HY196016
Descripción	Emibetuzumab (HY196016) is a research-grade recombinant antibody targeting Tyrosine-protein kinase Met. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Humanized
Isotipo	IgG4-kappa
Sistema de expresión	Mammalian Cells
Clonalidad	Monoclonal
Objetivo	Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Nivel de endotoxinas	Please contact the lab for this information.
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P08581
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Nombres alternativos	LA480, LY-2875358, 1365287-97-3
Fondo	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Nota	For research use only. Not suitable for clinical or therapeutic use.

Imágenes

SEC-HPLC

SEC-HPLC detection for Research Grade Emibetuzumab.
Bioactivity

Detects MET/c-Met/HGFR in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Emibetuzumab.
Western blot

Western blot analysis was performed using anti-MET/c-Met/HGFR monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human MET/c-Met/HGFR (Catalog No: HY196011)
Lane 2: negative control

Referencias

Datasheet

Research Grade Emibetuzumab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: support@abinScience.com

Lista de distribuidores

Research Grade Emibetuzumab